ES2342992T3 - Prediccion de un trastorno inflamatorio asociado con los polimorfismos de los loci de genes il-1. - Google Patents
Prediccion de un trastorno inflamatorio asociado con los polimorfismos de los loci de genes il-1. Download PDFInfo
- Publication number
- ES2342992T3 ES2342992T3 ES98922938T ES98922938T ES2342992T3 ES 2342992 T3 ES2342992 T3 ES 2342992T3 ES 98922938 T ES98922938 T ES 98922938T ES 98922938 T ES98922938 T ES 98922938T ES 2342992 T3 ES2342992 T3 ES 2342992T3
- Authority
- ES
- Spain
- Prior art keywords
- haplotype
- alleles
- allele
- disease
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 26
- 108010002352 Interleukin-1 Proteins 0.000 title claims abstract 7
- 102000054765 polymorphisms of proteins Human genes 0.000 title description 3
- 108700028369 Alleles Proteins 0.000 claims abstract description 145
- 102000054766 genetic haplotypes Human genes 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 37
- 208000017169 kidney disease Diseases 0.000 claims abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 10
- 206010024434 Lichen sclerosus Diseases 0.000 claims abstract description 9
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 9
- 208000004631 alopecia areata Diseases 0.000 claims abstract description 9
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 8
- 239000012472 biological sample Substances 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- 239000013068 control sample Substances 0.000 claims description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 238000005070 sampling Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 6
- 208000015023 Graves' disease Diseases 0.000 abstract description 8
- 208000003807 Graves Disease Diseases 0.000 abstract description 7
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 97
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 79
- 239000003550 marker Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 8
- 238000003205 genotyping method Methods 0.000 description 8
- 230000002969 morbid Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 description 7
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 7
- 208000003456 Juvenile Arthritis Diseases 0.000 description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102100039065 Interleukin-1 beta Human genes 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 208000028169 periodontal disease Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 206010022941 Iridocyclitis Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 241000219061 Rheum Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101150074243 Il1rn gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- LVKZSFMYNWRPJX-UHFFFAOYSA-N benzenearsonic acid Natural products O[As](O)(=O)C1=CC=CC=C1 LVKZSFMYNWRPJX-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000495 immunoinflammatory effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006012 semi-aromatic polyamide Polymers 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9711040.7A GB9711040D0 (en) | 1997-05-29 | 1997-05-29 | Prediction of inflammatory disease |
| GB9711040 | 1997-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2342992T3 true ES2342992T3 (es) | 2010-07-20 |
Family
ID=10813199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98922938T Expired - Lifetime ES2342992T3 (es) | 1997-05-29 | 1998-05-21 | Prediccion de un trastorno inflamatorio asociado con los polimorfismos de los loci de genes il-1. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US6268142B1 (OSRAM) |
| EP (1) | EP0983385B1 (OSRAM) |
| JP (1) | JP2002500513A (OSRAM) |
| CN (1) | CN1177059C (OSRAM) |
| AR (1) | AR016754A1 (OSRAM) |
| AT (1) | ATE462800T1 (OSRAM) |
| AU (1) | AU755107B2 (OSRAM) |
| BR (1) | BR9809183A (OSRAM) |
| CA (1) | CA2291731A1 (OSRAM) |
| DE (1) | DE69841588D1 (OSRAM) |
| EA (1) | EA199901097A1 (OSRAM) |
| ES (1) | ES2342992T3 (OSRAM) |
| GB (1) | GB9711040D0 (OSRAM) |
| IL (1) | IL133128A0 (OSRAM) |
| NO (1) | NO995803L (OSRAM) |
| PL (1) | PL337080A1 (OSRAM) |
| TW (1) | TWI236502B (OSRAM) |
| WO (1) | WO1998054359A1 (OSRAM) |
| ZA (1) | ZA984490B (OSRAM) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
| US6720141B1 (en) * | 1999-11-01 | 2004-04-13 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
| US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| TR200001263T2 (tr) * | 1997-11-07 | 2000-12-21 | Interleukin Genetics, Inc. | Kronik tıkayıcı solunum-yolu hastalığının teşhis ve terapötikleri |
| US6746839B1 (en) | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US20050032077A1 (en) * | 1998-03-10 | 2005-02-10 | Duff Gordon W. | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| GB2336431B (en) * | 1998-04-17 | 2003-06-25 | Johnson & Johnson Medical Ltd | Method of analysis of chronic wounds |
| AU769949B2 (en) * | 1998-04-21 | 2004-02-12 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6733967B1 (en) | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6251598B1 (en) | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| JP2003500005A (ja) * | 1999-02-10 | 2003-01-07 | インターリューキン ジェネティックス インコーポレイテッド | ＩＬ−１β遺伝子の突然変異に基づく治療および診断 |
| JP2002540801A (ja) * | 1999-04-02 | 2002-12-03 | インタールーキン ジェネティックス インク | 間質性肺疾患の危険性の予測 |
| IL147182A0 (en) * | 1999-06-30 | 2002-08-14 | Interleukin Genetics Inc | Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype |
| MXPA02002251A (es) * | 1999-08-30 | 2003-08-20 | Interleukin Genetics Inc | Diagnosticos y terapeuticos para osteoporosis. |
| US20090023147A1 (en) * | 1999-08-30 | 2009-01-22 | Kenneth Kornman | Diagnostics and therapeutics for osteoporosis |
| AU2001264659A1 (en) * | 2000-05-17 | 2001-11-26 | Board Of Regents, The University Of Texas System | Isolation of genes within sle-1b taht mediate a beak in immune tolerance |
| US20030124524A1 (en) * | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US20020168639A1 (en) * | 2000-09-22 | 2002-11-14 | Muraca Patrick J. | Profile array substrates |
| JP2002345500A (ja) * | 2000-12-22 | 2002-12-03 | Pfizer Prod Inc | 炎症性障害を発展させる増加したリスクを検出するための方法および試薬 |
| SG143977A1 (en) * | 2001-06-05 | 2008-07-29 | Auckland Uniservices Ltd | Methods and compositions for assessment of pulmonary function and disorders |
| EP1409737A4 (en) * | 2001-06-15 | 2005-10-12 | Interleukin Genetics Inc | METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING |
| WO2003072827A1 (en) * | 2001-10-31 | 2003-09-04 | Children's Hospital Medical Center | Method for diagnosis and treatment of rheumatoid arthritis |
| CN1753903B (zh) | 2001-11-19 | 2010-05-12 | 白介素遗传公司 | 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性 |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| KR100924468B1 (ko) | 2002-01-25 | 2009-11-03 | 인터레우킨 제네틱스, 인코포레이티드 | Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형 |
| WO2003100077A2 (en) * | 2002-05-20 | 2003-12-04 | Wisconsin Alumni Research Foundation | Label-free detection of single nucleotide polymorphisms using surface plasmon resonance imaging |
| US9388459B2 (en) * | 2002-06-17 | 2016-07-12 | Affymetrix, Inc. | Methods for genotyping |
| KR20040001552A (ko) * | 2002-06-28 | 2004-01-07 | 주식회사 인투젠 | 디엔에이 결합 단백질 비에 대한 자가항체에 결합할 수있는 단백질을 유효 성분으로 함유하는 전신성 경화증진단용 조성물, 이를 이용한 상기 자가항체의 검출 방법및 전신성 경화증 진단 방법 |
| US20040229228A1 (en) * | 2002-07-25 | 2004-11-18 | Northwestern University | Il-1 genotype in early kidney allograft rejection |
| WO2004029618A2 (en) * | 2002-09-30 | 2004-04-08 | Novartis Ag | Methods to predict cholesterol elevations during immunosuppressant therapy |
| CN1711361A (zh) * | 2002-10-15 | 2005-12-21 | 诺瓦提斯公司 | 预测药物治疗副效应水肿的方法 |
| AU2003291481A1 (en) * | 2002-11-11 | 2004-06-03 | Affymetrix, Inc. | Methods for identifying dna copy number changes |
| US10229244B2 (en) | 2002-11-11 | 2019-03-12 | Affymetrix, Inc. | Methods for identifying DNA copy number changes using hidden markov model based estimations |
| US7822555B2 (en) * | 2002-11-11 | 2010-10-26 | Affymetrix, Inc. | Methods for identifying DNA copy number changes |
| JP2007501627A (ja) | 2003-08-08 | 2007-02-01 | インタールーキン ジェネティックス インク | 骨粗鬆症のための診断法および治療法 |
| AU2005216298B2 (en) * | 2004-02-26 | 2010-09-02 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| US7309589B2 (en) | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
| RU2271827C1 (ru) * | 2004-09-28 | 2006-03-20 | Федеральное государственное учреждение"Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Федерального агенства по здравоохранению и социальному развитию"(ФГУ "СПбНИИ ЛОР Росздрава") | Способ определения тактики лечения рекомбинантным цитокином, регулирующим воспаление |
| WO2006097388A2 (en) * | 2005-02-08 | 2006-09-21 | Innogenetics N.V. | Nucleic acid variants in the c1qr1 gene associated with altered innate immunity. |
| US20060269946A1 (en) * | 2005-05-10 | 2006-11-30 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
| JP2008545389A (ja) * | 2005-05-19 | 2008-12-18 | シナージェンズ バイオサイエンス リミティド | 肺機能及び肺障害の評価のための方法及び組成物 |
| AU2006248201A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms |
| EP1888779A4 (en) * | 2005-05-20 | 2009-06-10 | Synergenz Bioscience Ltd | METHOD FOR THE ANALYSIS OF POLYMORPHISMS AND USES THEREOF |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| WO2007023148A2 (en) * | 2005-08-22 | 2007-03-01 | Innogenetics N.V. | Nucleic acid variants in the lbp gene associated with altered innate immunity |
| WO2007022590A1 (en) * | 2005-08-24 | 2007-03-01 | Genetic Technologies Limited | Identification of ancestral haplotypes and uses thereof |
| US8105775B2 (en) | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| US11306351B2 (en) | 2005-12-21 | 2022-04-19 | Affymetrix, Inc. | Methods for genotyping |
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| ES2431671T3 (es) * | 2006-11-15 | 2013-11-27 | Interleukin Genetics, Inc. | El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos |
| CN101230386B (zh) * | 2007-04-28 | 2011-09-14 | 廖凌虹 | 检测CYP2E1基因的单核苷酸多态性位点rs2480256的引物在制造用于评估系统性红斑狼疮易感性的试剂盒的用途 |
| US8200440B2 (en) | 2007-05-18 | 2012-06-12 | Affymetrix, Inc. | System, method, and computer software product for genotype determination using probe array data |
| US20080293589A1 (en) * | 2007-05-24 | 2008-11-27 | Affymetrix, Inc. | Multiplex locus specific amplification |
| EP2283156B1 (en) * | 2008-05-02 | 2015-11-11 | Interleukin Genetics, Inc. | Detecting genetic predisposition to osteoarthritis associated conditions |
| CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| CN102459596B (zh) * | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| EP2539449B9 (en) * | 2010-02-26 | 2018-09-05 | Qiagen GmbH | Process for parallel isolation and/or purification of rna and dna |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| US20120208187A1 (en) * | 2010-12-09 | 2012-08-16 | Kenneth Kornman | Method and Kit for Determining Severity and Progression of Periodontal Disease |
| US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| ES3015226T3 (en) | 2012-08-16 | 2025-04-30 | Veracyte Sd Inc | Prostate cancer prognosis using biomarkers |
| WO2014186036A1 (en) | 2013-03-14 | 2014-11-20 | Allegro Diagnostics Corp. | Methods for evaluating copd status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| CN103397022A (zh) * | 2013-07-17 | 2013-11-20 | 上海交通大学医学院附属瑞金医院 | 与Graves病或Graves眼病相关的核苷酸多态性标记及其应用 |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
| JP2019503176A (ja) | 2016-01-12 | 2019-02-07 | インターロイキン ジェネティクス， インコーポレイテッド | 処置に対する応答を予測するための方法 |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| US10337070B2 (en) | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| AU2018310987A1 (en) | 2017-08-04 | 2020-02-27 | Decipher Biosciences, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| DE102018104133B4 (de) * | 2018-02-23 | 2025-02-20 | Klinikum der Universität München, Anstalt des öffentlichen Rechts | Biomarker zur Feststellung einer möglichen Unverträglichkeit gegenüber Metallimplantaten |
| US12216128B2 (en) | 2018-04-12 | 2025-02-04 | Mayo Foundation For Medical Education And Research | Methods for guiding therapy decisions in seizure disorders |
| CN109295211A (zh) * | 2018-10-30 | 2019-02-01 | 深圳市万众基因转化医学研究院 | 一种人类斑秃相关基因突变筛查的组合引物及其应用 |
| CN113557036A (zh) | 2019-01-18 | 2021-10-26 | 奥泽生物疗法公司 | 基因编辑以改善关节功能 |
| WO2020215051A1 (en) * | 2019-04-19 | 2020-10-22 | Rpi Consulting Llc | Treatments for pregnancy-related conditions |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
| CA3186119A1 (en) * | 2020-07-16 | 2022-01-20 | Orthobio Therapeutics, Inc. | Gene editing to improve joint function |
| US20240327914A1 (en) * | 2021-07-08 | 2024-10-03 | Martin Levine | Devices, kits, and methods for determining increased susceptibility to and treatment and prevention of periodontitis, alzheimer’s disease, and other conditions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587605T2 (de) * | 1984-12-25 | 1994-03-17 | Dainippon Pharmaceutical Co | Interleukin-1 und dessen Derivat. |
| US5582979A (en) * | 1989-04-21 | 1996-12-10 | Marshfield Clinic | Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same |
| US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
| US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
| US5993817A (en) * | 1995-01-23 | 1999-11-30 | Xenotech | Method to ameliorate osteolysis and metastasis |
| US5686246A (en) | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
| US5942390A (en) | 1996-01-12 | 1999-08-24 | Cedars-Sinai Medical Center | Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism |
| US5698399A (en) * | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| GB9610281D0 (en) * | 1996-05-16 | 1996-07-24 | Ralston Stuart H | Diagnostic method and apparatus |
| GB9621129D0 (en) * | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| GB9706359D0 (en) | 1997-03-27 | 1997-05-14 | Gemini International Holdings | Polymorphisms of an il-1 receptor antagonist gene |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US6733967B1 (en) * | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| EP1409737A4 (en) * | 2001-06-15 | 2005-10-12 | Interleukin Genetics Inc | METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING |
| CN1753903B (zh) * | 2001-11-19 | 2010-05-12 | 白介素遗传公司 | 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性 |
-
1997
- 1997-05-29 GB GBGB9711040.7A patent/GB9711040D0/en active Pending
-
1998
- 1998-05-21 JP JP50035899A patent/JP2002500513A/ja active Pending
- 1998-05-21 DE DE69841588T patent/DE69841588D1/de not_active Expired - Lifetime
- 1998-05-21 AU AU75398/98A patent/AU755107B2/en not_active Ceased
- 1998-05-21 WO PCT/GB1998/001481 patent/WO1998054359A1/en not_active Ceased
- 1998-05-21 CA CA002291731A patent/CA2291731A1/en not_active Abandoned
- 1998-05-21 ES ES98922938T patent/ES2342992T3/es not_active Expired - Lifetime
- 1998-05-21 BR BR9809183-2A patent/BR9809183A/pt not_active Application Discontinuation
- 1998-05-21 EP EP98922938A patent/EP0983385B1/en not_active Expired - Lifetime
- 1998-05-21 PL PL98337080A patent/PL337080A1/xx unknown
- 1998-05-21 CN CNB98807656XA patent/CN1177059C/zh not_active Expired - Lifetime
- 1998-05-21 IL IL13312898A patent/IL133128A0/xx unknown
- 1998-05-21 EA EA199901097A patent/EA199901097A1/ru unknown
- 1998-05-21 AT AT98922938T patent/ATE462800T1/de not_active IP Right Cessation
- 1998-05-26 ZA ZA984490A patent/ZA984490B/xx unknown
- 1998-05-28 AR ARP980102477A patent/AR016754A1/es unknown
- 1998-05-29 TW TW087108415A patent/TWI236502B/zh not_active IP Right Cessation
-
1999
- 1999-06-30 US US09/345,217 patent/US6268142B1/en not_active Expired - Lifetime
- 1999-11-26 NO NO995803A patent/NO995803L/no not_active Application Discontinuation
-
2001
- 2001-04-27 US US09/845,129 patent/US6706478B2/en not_active Expired - Lifetime
-
2004
- 2004-03-15 US US10/802,061 patent/US20040152124A1/en not_active Abandoned
-
2007
- 2007-10-02 US US11/866,073 patent/US20080187920A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO995803L (no) | 2000-01-18 |
| US20080187920A1 (en) | 2008-08-07 |
| ATE462800T1 (de) | 2010-04-15 |
| PL337080A1 (en) | 2000-07-31 |
| AR016754A1 (es) | 2001-08-01 |
| NO995803D0 (no) | 1999-11-26 |
| US20040152124A1 (en) | 2004-08-05 |
| AU7539898A (en) | 1998-12-30 |
| CN1278868A (zh) | 2001-01-03 |
| CN1177059C (zh) | 2004-11-24 |
| US6268142B1 (en) | 2001-07-31 |
| EA199901097A1 (ru) | 2000-06-26 |
| US6706478B2 (en) | 2004-03-16 |
| EP0983385B1 (en) | 2010-03-31 |
| CA2291731A1 (en) | 1998-12-03 |
| AU755107B2 (en) | 2002-12-05 |
| IL133128A0 (en) | 2001-03-19 |
| ZA984490B (en) | 1998-12-02 |
| BR9809183A (pt) | 2000-08-01 |
| JP2002500513A (ja) | 2002-01-08 |
| US20020146700A1 (en) | 2002-10-10 |
| WO1998054359A1 (en) | 1998-12-03 |
| GB9711040D0 (en) | 1997-07-23 |
| DE69841588D1 (de) | 2010-05-12 |
| EP0983385A1 (en) | 2000-03-08 |
| TWI236502B (en) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU755107B2 (en) | Prediction of inflammatory disease associated with IL-1 geneloci polymorphisms | |
| Butler | Pediatric hypertension: Genetics of hypertension• current status | |
| JP6622731B2 (ja) | 歯周病の重症度および進行を決定するための改良された方法およびキット | |
| US20040053263A1 (en) | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease | |
| US20140272951A1 (en) | Methods of identifying mutations in nucleic acid | |
| US20080305967A1 (en) | Genetic Markers Associated with Endometriosis and Use Thereof | |
| WO2020133233A1 (zh) | 一种成骨发育不全疾病的致病突变及其检测试剂 | |
| US20090269761A1 (en) | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof | |
| US9305137B1 (en) | Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach | |
| WO2015184249A2 (en) | Sle and sle-related disease-associated risk markers and uses thereof | |
| US20120196286A1 (en) | Method and apparatus for diagnosing age-related macular degeneration | |
| CA2324866A1 (en) | Biallelic markers for use in constructing a high density disequilibrium map of the human genome | |
| US20130157873A1 (en) | Methods of assessing a risk of developing necrotizing meningoencephalitis | |
| JP4688492B2 (ja) | 炎症性疾患の判定方法 | |
| JP2006526986A (ja) | 炎症性大腸炎の診断方法 | |
| CN100545170C (zh) | 一种冠心病相关基因及其检测方法和用途 | |
| JP5644009B2 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
| US20070042364A1 (en) | Target genes for inflammatory bowel disease | |
| Kubistova et al. | Polymorphisms of the immune response genes: selected biological, methodical and medical aspects. | |
| Lanktree et al. | Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease | |
| Blanckenberg | Molecular genetics of arrhythmogenic right ventricular cardiomyopathy in South Africa | |
| CN112760369A (zh) | 一种检测诊断低钾血症致病基因的dna文库及其应用 | |
| JP2008502341A (ja) | 電位型カリウムチャネルをコードするヒト肥満感受性遺伝子およびその使用 | |
| CN113186274A (zh) | Grpel1突变基因、检测其的引物、试剂盒和方法以及其用途 | |
| Chai et al. | Genetic polymorphisms and periodontitis |